Morristown, NJ – According to filings with the U.S. Securities and Exchange Commission, Alitair Pharmaceuticals is raising $31,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Hoyes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alitair Pharmaceuticals

Alitair is a specialty pharmaceutical company focused on developing proprietary ion-exchange resin formulations, prescription cough medicines, and a pipeline of Orphan Drugs. Our proprietary formulation technology and portfolio of respiratory products address unmet medical needs. Our portfolio consists of patent protected, late-stage, well-characterized small molecules with clear regulatory paths to approval. We will utilize both the FDA 505(b)(2) and Orphan Drug pathways to reduce development costs, shorten approval timelines, and optimize the chances of FDA approval. Our prescription cough and bronchiectasis pipeline products will compete in large established markets that together exceed $7 billion in potential. Our lead prescription cough product, benzonatate, is formulated into a twice-a-day tablet that could provide safety, convenience, and compliance benefits to patients. And, it is a non-narcotic option for physicians and patients.

To learn more about Alitair Pharmaceuticals, visit http://alitairpharmaceuticals.com/

Contact:
James Hoyes, Chief Executive Officer
877-388-1464
https://www.linkedin.com/in/james-hoyes-b838a346/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved